Cookies help us deliver our services. By using our services, you agree to our use of cookies. More information

Schiller 2022 Pharmaceuticals (Basel)

From Bioblast
Publications in the MiPMap
Schiller J, Zickermann V (2022) Binding of natural inhibitors to respiratory complex I. https://doi.org/10.3390/ph15091088

Β» Pharmaceuticals (Basel) 15:1088. PMID: 36145309 Open Access

Schiller Jonathan, Zickermann Volker (2022) Pharmaceuticals (Basel)

Abstract: NADH:ubiquinone oxidoreductase (respiratory complex I) is a redox-driven proton pump with a central role in mitochondrial oxidative phosphorylation. The ubiquinone reduction site of complex I is located in the matrix arm of this large protein complex and connected to the membrane via a tunnel. A variety of chemically diverse compounds are known to inhibit ubiquinone reduction by complex I. Rotenone, piericidin A, and annonaceous acetogenins are representatives of complex I inhibitors from biological sources. The structure of complex I is determined at high resolution, and inhibitor binding sites are described in detail. In this review, we summarize the state of knowledge of how natural inhibitors bind in the Q reduction site and the Q access pathway and how their inhibitory mechanisms compare with that of a synthetic anti-cancer agent.

β€’ Bioblast editor: Plangger M


Labels:



Enzyme: Complex I